anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Upon enrollment, participants will receive an electronic link to an enrollment survey to assess their baseline perceptions of diabetes and weight-based stigma, attitudes towards and intentions to engage in condition management behaviors, sociodemographic and clinical factors (e.g., gender, age, race, and ethnicity) and potential moderators, including diabetes distress, anxiety, depression, history of weight-based victimization, and stigma consciousness. Participants will then be randomly assigned to either the self-affirmation intervention or a waitlist control condition (participants in the waitlist control will have the option to receive the same intervention as participants in the experimental condition at end of the study period). Participants will be using the randomization module in our online survey vendor, REDCap. This module allows researchers to program REDcap to automatically randomize participants in their study to one of the arms or conditions of their study. Before every 3-month wellness visit with their endocrinologist, participants will receive an electronic prompt to complete a self-affirmation writing induction. To complete the writing induction, participants will review a list of values and are instructed to choose up to two that are important to them. Next, participants are asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges. Participants in the waitlist control condition will also complete writing exercises but they will be abbreviated (this in the psychological literature is referred to as a "low affirmation condition"). At the end of the study, waitlist control participants will have access to the full exercise should they like to receive it. After their 3-month wellness visit, participants will be sent an electronic link to the post-intervention survey. This will assess to assess their baseline perceptions of diabetes and weight-based stigma, attitudes towards and intentions to engage in condition management behaviors. In total, participants will complete 4 writing inductions and 4 post-evaluation surveys over the course of a year. In addition to writing inductions and survey data, aggregated data from participants' continuous glucose monitors will be collected throughout the study period to assess time spend in target glucose range. The investigators will also collect participants' most recent pre-and-post intervention Hemoglobin A1C (HbA1c) measurements via EHR data to assess longitudinal changes in glucose control. To evaluate the effectiveness of our intervention, the investigators will test whether mean scores in 1) post-intervention stigma and stigma-induced identity threat scores; 2) average confidence in and intentions to engage in condition management scores; and 3) average time spent in target glycemic target range significantly differ between conditions.
PROBLEM TO BE SOLVED: To provide a new protein composed of a protein containing a specific amino acid sequence, having γ-aminobutyric acid(GABA) transporter activity and useful e.g. as a prophylactic and therapeutic agent for various nervous diseases, dementia, etc. SOLUTION: This new protein (salt) contains an amino acid sequence same as or essentially same as the amino acid sequence of formula. It has γ- aminobutyric acid(GABA) transporter activity and is useful e.g. as a prophylactic and therapeutic agent for anxiety, convulsion, epilepsy, schizophrenia, cerebrovascular disorder, cerebral paralysis, spondylosis deformans, catatonic headache, lumbago, cervico-humero-branchial syndrome and dementia. The protein can be produced by using an mRNA, etc., separated from the cell and tissue of human kidney, etc., as a template, carrying out RT-PCR using a primer composed of a partial base sequence, linking the obtained gene to a plasmid, etc., transforming a host cell such as E.coli and culturing the transformant.
Participants first received ZOCOR 40 mg film-coated tablet 1 tablet (Reference product) in a fasting state. After a washout period of 1 week, they then recieved Simvastatin 40 mg film-coated tablet (Test product) in a fasting state.
BACKGROUND: Gibberella ear rot (GER) is one of the most devastating diseases in maize growing areas, which directly reduces grain yield and quality. However, the underlying defense response of maize to pathogens infection is largely unknown.
RESULTS: To gain a comprehensive understanding of the defense response in GER resistance, two contrasting inbred lines 'Nov-82' and 'H10' were used to explore transcriptomic profiles and defense-related phytohormonal alterations during Fusarium graminearum infection. Transcriptomic analysis revealed 4,417 and 4,313 differentially expressed genes (DEGs) from the Nov-82 and H10, respectively, and 647 common DEGs between the two lines. More DEGs were obviously enriched in phenylpropanoid biosynthesis, secondary metabolites biosynthesis, metabolic process and defense-related pathways. In addition, the concentration of the defense-related phytohormones, jasmonates (JAs) and salicylates (SAs), was greatly induced after the pathogen infection. The level of JAs in H10 was more higher than in Nov-82, whereas an opposite pattern for the SA between the both lines. Integrated analysis of the DEGs and the phytohormones revealed five vital modules based on co-expression network analysis according to their correlation. A total of 12 hub genes encoding fatty acid desaturase, subtilisin-like protease, ethylene-responsive transcription factor, 1-aminocyclopropane-1-carboxylate oxidase, and sugar transport protein were captured from the key modules, indicating that these genes might play unique roles in response to pathogen infection, CONCLUSIONS: Overall, our results indicate that large number DEGs related to plant disease resistance and different alteration of defensive phytohormones were activated during F. graminearum infection, providing new insight into the defense response against pathogen invasion, in addition to the identified hub genes that can be further investigated for enhancing maize GER resistance.
<P>PROBLEM TO BE SOLVED: To provide a detergent that is obtained by application of a fermentation technology and a manufacturing method therefor, wherein a detergent is realized that shows an increased saponification rate of oil and fat, and improved detergency at the same time, and that provides useful microorganisms that proliferate in the waste water after cleaning to purify the water, serving as a water purification material after cleaning, by adding flora of useful microbes and an EM-X ceramic powder shown below, to the soap manufacturing process.  <P>SOLUTION: Microbes are selected as an organic body that serves as a starter of environmental purification processes. Among them, flora of useful microbes (EM) composed mainly of floras of facultative anaerobic lactic acid bacilli, yeast and photosynthesis bacteria, as well as the following EM-X ceramic powder are introduced into the soap manufacturing process. By this, the treated product thus obtained acts as a substrate for benign microbes or as a microbial material to realize an environmental purification effect. In the above description, the above-described EM-X ceramic powder is a ceramic powder obtained by mixing a condensed liquid of antioxidant materials produced by the flora of useful microbes (EM) and EM into clay, followed by aging and baking the mixture at 800-1,200°C.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Chronic neck pain is a serious health problem with low quality of life, disability and economical burdens. Studies have found that nearly 83% of chronic neck pain patients had changes in breathing patterns. Compensated breathing pattern by using the neck-accessory respiratory muscles may result in excessive muscle strains and over-activations, which may also contribute to develop chronic neck pain. The diaphragm is the most important respiratory muscle which attached to the ribs and spine, and thus has an influence on spinal stability. Few studies have showed that diaphragm releasing and breathing training can reduce pain and improve flexibility of posterior chain muscles, spinal range of motions, and ribcage excursions in asymptomatic adults and patients with low back pain. However, the effects in patients with chronic neck pain has not bee determined. Therefore, there are two main purpose of this study. First, to determine the relationships among diaphragm mobility, neck pain and dysfunction, and respiratory in patients with chronic neck pain. Second, to investigate the effects of diaphragm releasing, breathing training, or combined intervention on pain and disability in patients with chronic neck pain. It is expected to recruit 150 patients with chronic neck pain and 30 healthy volunteers. Patients with chronic neck pain will be randomly assigned to (1) manual therapy group (2) manual control group (3) breathing training group (4) general exercise control group (5) manual therapy combined breathing training group. Each participant will receive a specific intervention program depending on their group allocation. All participants will receive two evaluation sessions before and after the intervention including ultrasonography, cervical and thoracic function, respiratory functions, and autonomic balance.
The invention comprises podophyllotoxin b -D-glucoside, C28H32O13, m.p. 149-152 DEG  C., and a process for its isolation from Podophyllum peltatum L. or Indian Podophyllum emodi Wall by extracting the rhizome (which has been freed from ether-soluble and -chloroform-soluble resins) with a water-soluble lower alkanol, concentrating the extract, dissolving the residue in aqueous alcohol, treating the solution with tannin-precipitating agents, e.g. lead salts, ferric hydroxide, to separate the glucoside from its tannin-complex, separating from the precipitated impurities, concentrating the residual solution, diluting it with water, and extracting the glucoside from the aqueous solution with water-immiscible organic solvents which may preferably contain small quantity of water-soluble alcohols, from which the glucoside is finally obtained by evaporation of solvent. The new glucoside is soluble in water and in alcohol and by enzymatic cleavage or acid hydrolysis yields podophyllotoxin and D-glucose.  In examples: (1) dried and powdered rhizomes of Podophyllum emodi Wall are extracted first with chloroform and then with methanol, the latter extracts concentrated to 1/2 volume and an equal volume of water added, tannins are then precipitated with excess lead acetate, filtrate is concentrated, extracted with chloroform, and then chloroform-ethanol from which the glucoside is isolated and then purified by chromatography on silica gel.  (2) As in (1) using rhizomes from Podophyllum peltatum L., and effecting purification either as above or by partition between water and ethyl acetate.
Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.
This initial study is a pilot study which is going to test the safety and efficacy of the developed ultrasound intervention for osteoarthritis, initially on osteoarthritis of the knee. This study is a pilot study to evaluate two distinct variables. The first is the safety and efficacy of the device, and the second is the potential impact the device may have on patients as their osteoarthritic joints react to the LFU, using patient-reported outcomes associated with this study. The ultrasound will be delivered at a frequency of 33 kHz at power levels of 4-10 Pascals with a program of 1.6 seconds on and 1.6 seconds off. The generators will be encased in epoxy within the Osteoarthritis baths. The intervention will be repeated on every second or third day to allow time for healing
The invention provides recombinant viruses comprising heterologous envelope proteins capable of mediating entry of the recombinant viruses into host cells. In one embodiment, a recombinant virus of the invention is a member of the Paramyxovirzdae family (e.g., a respiratory syncytial virus), and the heterologous envelope protein includes the ectodomain of a baculovirus envelope protein (e.g., the GP64 protein). In some cases, the heterologous envelope protein is provided in addition to homologous envelope proteins) which may or may not be functional. The heterologous protein can provide the recombinant virus with enhanced stability (e.g., at 4 °C, 22 °C, or 37 °C), and allows production of high-titer virus stocks. The heterologous protein can also impart temperature sensitivity to the replication of the recombinant virus. In addition, the recombinant virus can be designed to be infectious but incapable of spreading between host cells by providing the heterologous protein by complementation in trans. These features attenuate the disease-causing potential of the recombinant virus, therefore increasing its safety of use as vaccines.
BACKGROUND: Despite the success of sleeve gastrectomy (SG) in of weight loss and treatment of the medical problems associated with obesity, some concerns have arisen about the need for revisional surgeries after SG in some patients. This study aimed to present an updated and comprehensive comparison among the presently available revisional surgeries employed explicitly in cases of inadequate outcomes after SG, which is the most frequently performed bariatric surgery in contemporary practice.
METHODS: This network meta-analysis included studies that compared the outcomes of different revisional bariatric procedures after an inadequate outcome of SG.
RESULTS: Searching across the electronic databases yielded 31 eligible articles. Re-SG was associated with the highest rate of significant complications. Patients treated with single anastomosis duodenal-ileal bypass (SADI) had a significantly higher percentage of total weight loss (%TWL) than those treated with one anastomosis gastric bypass (OAGB) and Roux-en-Y gastric bypass (RYGB). The percentage of excess weight loss (%EWL) at the end of the follow-up period was significantly higher in patients in the SADI group compared to those in the RYGB group and the OAGB, and re-SG exhibited the least values compared to SADI, biliopancreatic diversion with duodenal switch (BPD/DS), and OAGB. Significantly lower rates of reflux worsening/de novo development were observed in the SADI group compared to the OAGB group and the re-SG group, which showed significantly higher rates than SADI and RYGB.
CONCLUSION: Our comprehensive network meta-analysis highlights SADI as a promising revisional option post-SG, demonstrating superior weight loss outcomes, lower significant complication rates, and a favorable impact on reflux compared to other procedures. While acknowledging the limitations of our study, these findings support the potential efficacy of SADI in addressing the challenges of inadequate weight loss after sleeve gastrectomy.
Systems, methods and devices for validating and performing operations on homomorphically encrypted data are described herein. The methods include securely transmitting and extracting information from encrypted data without fully decrypting the data. A data request may include an encrypted portion including a set of confidential data. One or more sets of encrypted comparison data may be then retrieved from a database in response to the data request. The encrypted set of confidential data from the data request is then compared with each set of encrypted comparison data using one or more homomorphic operations to determine which set of encrypted comparison data matches the encrypted set of confidential data. If there is a match, this validates the set of confidential data. An encrypted indicator is then generated indicating success or failure in validating the set of confidential data, which may then be forwarded to a party associated with the data request.
The purpose of this project is to evaluate a currently active community-based Recreational Therapy (RT) Wellness Recovery Program (WRP) for individuals with Parkinson's disease (PD) to determine the efficacy of the treatment intervention. Since PD is a progressive, degenerative neurological disease, it is critical that individuals with this diagnosis remain as active as possible to slow down the progression of the disease, improve balance and strength, and increase health-related quality of life. The overall goal of this project is to determine the efficacy of a neuroplasticity physical activity program in terms of improving balance, improving health-related quality of life, reducing stress, and increasing satisfaction in exercise including social connectedness of group exercise. There is evidence that the neuroplasticity model may be a more effective type of intervention than traditional exercise programs in improving symptoms of PD. The neuroplasticity approach requires repetition of complex tasks that are high intensity and present a novel challenge. This type of intervention has been shown to improve motor and cognitive behaviors which are critical areas of decline for those with PD. The WRP program uses a comprehensive neuroplasticity-principled program that integrates exercise and wellness. The PI, Julie Bradwell, LRT/CTRS is a Certified Instructor for Parkinson Wellness Recovery Power Moves. The RT Wellness Recovery program at Wake Forest Baptist Health is modeled on the Parkinson Wellness Recovery Power Moves. Components within the program include the Parkinson Power Moves and the exercise 4 Brain Change. This study will be a 14-week study with the first two weeks of collecting baseline data and immediately following with a 12-week intervention program to increase balance, health-related quality of life, and satisfaction in exercise in individuals with PD as well as reduce stress. Most research on RT interventions for this population are in traditional settings (inpatient or rehabilitation settings). When discharged from these settings, many individuals become less active, have few social interactions and lose the benefits of exercise and physical therapy they gained while in these programs once they are home. The WRP community-based program at Wake Forest Baptist Health has the potential to prevent secondary complications as well as slow down the progression of the disease for participants. If the outcomes of this project suggest this type of intervention will improve the functional skills, quality of life, and/or satisfaction in exercise for individuals with PD and reduce stress, it will provide the RT discipline with evidenced based practice intervention for this population
Controlled-release pharmaceuticals are prepared by mixing starting materials and a process medium in a reactor to form a supercritical fluid slurry. The starting materials include a biologically active ingredient and a polymer. The process medium preferably is carbon dioxide which is supplied to the reactor in a supercritical state or which is heated and pressurized in the reactor to attain a supercritical state. After mixing for a period of time, the slurry either is left in the reactor or is discharged into a receiving vessel. The process medium is separated from the other materials and removed, leaving behind finely divided particles. The particles comprise porous particles of polymer that are infused with the biologically active ingredient. The finely divided particles can be incorporated into tablets, capsules, or the like for ingestion by patients.
The invention relates to a method and device for determining a characteristic value (ΔE) relating to the blood circulation of modified, especially pigmented tissue regions (12) in organs of living beings, for example of the skin (10). A first and a second blood volume flow are determined by means of a laser fluxmeter at a first (14) and a second (16) measurement point within the modified tissue region (12) and within the surrounding, non-modified tissue region, as measurement curves (20, 22) of a volume flow signal (LDF) depending on the time (t). A wavelet analysis of the measurement curves (20, 22) is then carried out as a three-dimensional representation of the signal intensity on a frequency or scale axis (s) and with time (t). The curve of a vasomotion energy (E) on the frequency or scale axis (s) is determined for the measurement curves (20, 22), which are subjected to the wavelet analysis, whereby said vasomotion energy (E) is the integral of the signal intensity over the time for a determined frequency or scale value (s). The vasomotion energy (E) curve of the second measurement curve (22) is subtracted from the vasomotion energy (E) curve of the first measurement curve (20), such that a differential curve is formed. The differential curve is then integrated, in order to obtain the characteristic value (ΔE).
Primary Nocturnal Enuresis: The dosage of Desmopressin Acetate Tablets must be determined for each individual patient and adjusted according to response. Patients previously on intranasal desmopressin acetate therapy can begin tablet therapy the night following (24 hours after) the last intranasal dose. The recommended initial dose for patients age 6 years and older is 0.2 mg at bedtime. The dose may be titrated up to 0.6 mg to achieve the desired response. Fluid restriction should be observed, and fluid intake should be limited to a minimum from 1 hour before desmopressin acetate administration, until the next morning, or at least 8 hours after administration. (See WARNINGS, PRECAUTIONS, Pediatric Use and Geriatric Use.)
Patients randomized to escitalopram, will initiate treatment at 5 mg qAM for 1 week and then 10 mg qAM (the recommended starting dose for adolescents 12-17 years and the dose used in the pediatric registration trials). After Week 4 (V5), escitalopram will be increased to 15 mg and this dose will be continued until either Week 6 (V6) or the end of the acute phase of the study; however, at Week 6 (V6), escitalopram may be increased to 20 mg qAM based on efficacy.
The present invention relates to restorative materials, in particular to glass-ionomer cements. More particularly, the present invention relates to glass-ionomer cements having particular utility in the repair of human hard tissue, in particular as dental restorative materials and in orthopaedic surgery. We describe a composition comprising a mixture of a glass ionomer cement and zinc phosphate. Preferably, the composition comprise from 40 to 95% by weight of glass ionomer cement and from to 60% by weight of zinc phosphate. The present invention also provides a powdered composition comprising a fluorosilicate glass and deactivated zinc oxide. Such that the zinc phosphate is formed in sith by reaction between the zinc oxide and phosphoric acid.
The estimated radiation absorbed doses for adults from intravenous injection of Amyvid are shown in Table 1. 

The effective dose resulting from a 370 MBq (10 mCi) dose of Amyvid is 7.0 mSv in an adult, (19 x 370 = 7030 μSv = 7.030 mSv). The use of a CT scan to calculate attenuation correction for reconstruction of Amyvid images (as done in PET/CT imaging) will add radiation exposure. Diagnostic head CT scans using helical scanners administer an average of 2.2 ± 1.3 mSv effective dose (CRCPD Publication E-07-2, 2007). The actual radiation dose is operator and scanner dependent. The total radiation exposure from Amyvid administration and subsequent scan on a PET/CT scanner is estimated to be 9 mSv.